Literature DB >> 9218734

Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers.

N P Michell1, M J Langman, M C Eggo.   

Abstract

We have compared the expression of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in ten paired samples of normal and tumour colonic tissue with regard to both mRNA and protein. We have compared sensitivity of these tissues to IGF-I using primary cultures of epithelial cells of colonic mucosa, and we have examined the production of IGFs and IGFBPs by these cells. In the tissues, IGFBP-2 mRNA was expressed in all normal and cancer samples but other IGFBPs showed variable expression. mRNAs for IGF-I were expressed in all normal and cancer tissues but IGF-II mRNA was only detected in cancer tissue (3 out of 10). Immunostaining of sections of normal and cancer tissue was negative for IGF-I and IGF-II; IGFBP-2 was positive in 2 out of 10 cancer tissues and 7 out of 10 normal tissues; IGFBP-3 was positive in 7 out of 10 cancer tissues and 7 out of 10 normal tissues; and IGFBP-4 was positive in 5 out of 10 cancer tissues and 6 out of 10 normal tissues. In the cells in culture, cancer cells showed increased incorporation of [35S]methionine into protein and [3H]thymidine into DNA (P < 0.02) when treated with IGF-I. Western blotting of serum-free conditioned media from cells in culture showed that 8 out of 10 normal and 3 out of 10 cancer cultures produced a 32-kDa immunoreactive IGFBP-2. No IGFBP-3 was secreted by any culture but 24-kDa IGFBP-4 was found in 3 out of 10 normal and 5 out of 10 cancer tissues. Because of the discrepancy between mRNA and protein expression for IGFBP-2, degradation of native IGFBPs was assessed using tissue extracts. Colon cancer extracts were able to degrade exogenous IGFBP-2, IGFBP-3 and IGFBP-4, whereas normal tissue extracts were without effect on IGFBP-2. We conclude that IGFBPs are synthesized and secreted by cells of the colonic mucosa but that proteolysis of secreted IGFBP-2 occurs in colon cancer tissue. This selective degradation may confer a growth advantage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218734      PMCID: PMC2223789          DOI: 10.1038/bjc.1997.337

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

Review 1.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations.

Authors:  W H Daughaday; P Rotwein
Journal:  Endocr Rev       Date:  1989-02       Impact factor: 19.871

2.  Insulin-like growth factor binding proteins in maternal serum throughout gestation and in the puerperium: effects of a pregnancy-associated serum protease activity.

Authors:  L C Giudice; E M Farrell; H Pham; G Lamson; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins.

Authors:  R C Baxter; J L Martin; M I Tyler; M E Howden
Journal:  Biochem Biophys Res Commun       Date:  1986-09-30       Impact factor: 3.575

5.  Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level.

Authors:  G K Haselbacher; J C Irminger; J Zapf; W H Ziegler; R E Humbel
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

6.  Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer.

Authors:  J A Foekens; H Portengen; M Janssen; J G Klijn
Journal:  Cancer       Date:  1989-06-01       Impact factor: 6.860

7.  Culture of human gastrointestinal epithelial cells.

Authors:  M P Moyer
Journal:  Proc Soc Exp Biol Med       Date:  1983-10

8.  Expression of insulin-like growth factor-II transcripts in Wilms' tumour.

Authors:  A E Reeve; M R Eccles; R J Wilkins; G I Bell; L J Millow
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

9.  Abnormal expression and structural modification of the insulin-like growth-factor-II gene in human colorectal tumors.

Authors:  S Lambert; J Vivario; J Boniver; R Gol-Winkler
Journal:  Int J Cancer       Date:  1990-09-15       Impact factor: 7.396

10.  Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells.

Authors:  C Lalou; C Silve; R Rosato; B Segovia; M Binoux
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

View more
  13 in total

1.  IGF1/IGF1R and microRNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells.

Authors:  Zhenjun Li; Weihuo Pan; Yi Shen; Zhiliang Chen; Lihua Zhang; Yuping Zhang; Quan Luo; Xiaojiang Ying
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

Review 2.  The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge.

Authors:  Rajaraman Durai; Wenxuan Yang; Sharmila Gupta; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2005-01-14       Impact factor: 2.571

3.  Insulin like growth factor binding protein 4 promotes GBM progression and regulates key factors involved in EMT and invasion.

Authors:  V R Praveen Kumar; Priyanka Sehgal; Balram Thota; Shilpa Patil; Vani Santosh; Paturu Kondaiah
Journal:  J Neurooncol       Date:  2014-01-07       Impact factor: 4.130

4.  Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.

Authors:  Todd W Bauer; Fan Fan; Wenbiao Liu; Marjorie Johnson; Nila U Parikh; Graham C Parry; Jennifer Callahan; Andrew P Mazar; Gary E Gallick; Lee M Ellis
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

5.  A case of colorectal carcinoma in adenoma analyzed by a cDNA array.

Authors:  Katsuhiko Nosho; Hiroyuki Yamamoto; Hiroyuki Takamaru; Yasuo Hamamoto; Akira Goto; Yukinari Yoshida; Yoshiaki Arimura; Takao Endo; Koichi Hirata; Kohzoh Imai
Journal:  Int J Colorectal Dis       Date:  2004-10-15       Impact factor: 2.571

6.  IGFBP-2 - taking the lead in growth, metabolism and cancer.

Authors:  Steven W Yau; Walid J Azar; Matthew A Sabin; George A Werther; Vincenzo C Russo
Journal:  J Cell Commun Signal       Date:  2015-01-25       Impact factor: 5.782

7.  De Novo proteome analysis of genetically modified tumor cells by a metabolic labeling/azide-alkyne cycloaddition approach.

Authors:  Seda Ballikaya; Jennifer Lee; Uwe Warnken; Martina Schnölzer; Johannes Gebert; Jürgen Kopitz
Journal:  Mol Cell Proteomics       Date:  2014-09-15       Impact factor: 5.911

8.  Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells.

Authors:  Şeyda Berk; Joseph A M J L Janssen; Peter M van Koetsveld; Fadime Dogan; Naci Değerli; Servet Özcan; Fahrettin Kelestimur; Leo J Hofland
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

9.  The insulin and igf-I pathway in endocrine glands carcinogenesis.

Authors:  Roberta Malaguarnera; Alaide Morcavallo; Antonino Belfiore
Journal:  J Oncol       Date:  2012-08-08       Impact factor: 4.375

10.  Inducing apoptosis of human colon cancer cells by an IGF-I D domain analogue peptide.

Authors:  Shi Yu Yang; Kevin M Sales; Barry J Fuller; Alexander M Seifalian; Marc C Winslet
Journal:  Mol Cancer       Date:  2008-02-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.